B2BROKER
28.1.2020 11:15:06 CET | Business Wire | Press release
B2Broker, a leading liquidity and technology provider of solutions to the Forex and crypto industry, has signed an agreement with Devexperts , a financial software developer, to license their dxTrade platform. dxTrade is a multi-asset trading solution for brokers which, unlike other existing OTC trading platforms, supports the entire spectrum of assets. This feature will allow B2Broker to become the leading Prime of Prime liquidity provider in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005354/en/
B2Broker’s pool of trading platforms currently includes OneZero Hub, PrimeXM xCore, several MT4 and MT5 trading platforms, together with B2Trader (the company’s own Matching Engine platform). With the addition of dxTrade, clients will be able to gain quick and easy access to one of the deepest liquidity pools in the industry for Stocks/Equities, ETFs, CFDs, Futures, Vanilla Options, Commodities, Metals, Forex, Crypto Futures, Crypto Spot, Crypto CFD and Bonds.
The company, which recently expanded its Crypto CFD liquidity offering with the addition of 61 new crypto pairs, now totalling 100 pairs, is recognised as being one of the industry’s leading LPs, offering the highest level of support with 24/7 trading and support in English, Russian, Chinese Cantonese and Simplified, Arabic, Spanish, Hindu, Italian, Urdu, Farsi, Pashto, Hebrew and Turkish.
B2Broker recently completed its integration with the dxTrade platform in order to spread liquidity amongst brokers who already use dxTrade, and to offer it to newly established or expanding brokers. From now on, they will be able to connect to one of the largest liquidity pools in the industry in just one minute through FIX API or by connecting to dxTrade directly.
Moreover, B2Broker has integrated B2Core with dxTrade. B2Core, the new name for Trader’s Room , is a ready-made functional solution for brokerages which allows clients to verify and register customers and perform functions such as accepting and sending payments, make deposits and withdrawals and open accounts, etc. Companies who use the dxTrade platform can quickly get connected to B2Core prior to launching their own brokerage business.
Finally, the company’s cryptocurrency payment gateway, B2BinPay , has also been integrated with dxTrade, enabling clients to securely and cost-effectively send, receive, store, exchange and accept cryptocurrency payments online.
Arthur Azizov, Founder and CEO of B2Broker commented, “Our goal to become a global Prime of Prime liquidity provider became a reality thanks to our tailored version of dxTrade which, in combination with our technology and depth of liquidity, makes our offering unmatchable in the industry.”
Evgeny Sorokin, SVP of Software Engineering, Devexperts added: “We are pleased that B2Broker has chosen our modular multi-asset trading platform. dxTrade can be configured to serve different clients in different markets and I am certain that our technology will assist B2Broker with their expansion.”
About B2Broker
B2Broker is a liquidity and technology provider of solutions for the crypto and foreign exchange industry. The company specialises in the sphere of B2B services and products, catering for a wide range of clients including large licensed brokers, crypto exchanges, crypto brokers, forex brokers, hedge and crypto funds and professional managers.
B2Broker’s advanced base of ready to use technical solutions enable brokers to save time and money on consuming infrastructure projects and focus on enlarging their client base and increasing their revenues.
About Devexperts
Devexperts specializes in the development of tailored software solutions for the Capital Markets industry with clients including retail and institutional brokerage houses, exchanges, and wealth management firms. Devexperts are the developers of the thinkorswim platform and numerous recognized and reliable financial applications, with millions of traders using their technology daily. The services from Devexperts include low-latency market data feeds, AR/VR data visualization, AI digital assistants, deep learning, and market analysis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005354/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom